风湿病大会摘要前瞻：安进干燥病药物显优势，两款现货型CAR-T初显疗效
高盛认为，安进dazodalibep在改善干燥症状方面略有差异化；两款异体CAR-T的早期数据也令人鼓舞，但患者数和随访时间仍有限。
Goldman Sachs ·
Topic：Pharmaceuticals
Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.
Topchoice Medical：种植量增长被价格下滑抵消，全年病例指引下调
2026年第三季度种植病例同比增长15%，但均价下降10%，收入增幅仅3.6%。管理层下调全年病例指引，高盛随之下修盈利预测和目标价。
Goldman Sachs ·
BioNTech乳腺癌试验达标但获益有限，花旗认为股价冲击可控
T-pam三期试验达到主要终点，但无进展生存期获益有限、间质性肺病发生率较高。花旗认为此前下调的预期减轻了结果对BioNTech的冲击，同时关注子宫内膜癌机会及其他肿瘤管线。
Citi ·
凯莱英三季度小分子业务回暖，新兴业务放缓加大四季度交付压力
三季度营收和核心经营利润均低于市场共识，归母净利润超预期则主要来自非经常性收益。公司维持全年增长指引，意味着四季度收入需较三季度显著跃升。
Bernstein ·
Gan & Lee Pharmaceuticals' third-quarter results miss expectations: Overseas licensing revenue delayed, while innovative drug progress supports growth outlook
Third-quarter revenue rose 16.9% year on year, but Goldman Sachs said a delay in recognizing business development and licensing revenue weighed on results. Overseas sales and two innovative drug candidates made progress, while potentially higher R&D spending prompted Goldman Sachs to lower its earnings forecasts for the next two years.
Goldman Sachs ·
WuXi AppTec raises revenue guidance: Late-stage projects accelerate orders as capacity expansion pressures margins
In the first three quarters of 2026, new orders for WuXi AppTec’s continuing operations rose more than 60% year over year at constant exchange rates. Citi raised its earnings forecasts and target prices while factoring in the potential erosion of chemistry gross margins from new capacity.
Citi ·
IQVIA’s third-quarter orders and revenue beat expectations, but acquisitions drove the increase in full-year guidance
Research & Development Solutions drove IQVIA’s third-quarter earnings beat, while order momentum also supported improving demand. At the same time, the backlog cleanup was larger than expected, and full-year organic growth guidance was trimmed slightly.
J.P. Morgan ·
WuXi AppTec’s orders and margins rise, while overseas expansion costs and US policy still shape the outlook
Third-quarter profit grew faster than revenue, and the company raised its full-year guidance again. JPMorgan sees growth from late-stage projects and commercial manufacturing, but the timing of large-order deliveries and the ramp-up of overseas capacity will affect when results materialize.
J.P. Morgan ·
Hengrui’s third-quarter innovative drug growth rises to 24%; licensing revenue and lower expense ratios drive profit above expectations
Morgan Stanley says Hengrui’s third-quarter revenue and profit were both slightly above market consensus: innovative drug sales accelerated and recognized collaboration revenue increased, but generic drug sales continued to decline and product gross margin also fell.
Morgan Stanley ·
Amgen’s Sjögren’s drug phase three data update: Both dosing regimens meet primary endpoint, with improvement in dryness symptoms
Dazodalibep met the primary endpoint in patients with systemic disease activity, and dosing every four weeks also improved patient-reported dryness symptoms. Morgan Stanley considers it highly competitive, although differences in placebo responses limit cross-trial comparisons.
Morgan Stanley ·
Pharmaron’s third-quarter revenue grows 21%: CMC leads, while exchange rates weigh on laboratory gross margin
Pharmaron’s third-quarter revenue came in slightly above the Bloomberg consensus, with CMC leading in revenue and new-order growth; exchange-rate effects and higher finance costs caused net profit attributable to shareholders to grow more slowly than revenue.
Nomura ·
Hengrui Pharma's drug sales return to growth in the third quarter as collaboration revenue boosts profit
Nomura estimates that Hengrui's third-quarter drug sales grew 4.9% year on year, reversing the previous quarter's decline. A sharp increase in collaboration revenue pushed total revenue and net profit attributable to shareholders above Bloomberg consensus estimates, although full-year growth in innovative drug sales may fall short of the company's target set at the start of the year.
Nomura ·
U.S. midterm elections could ease pressure from healthcare cuts; Bernstein favors Medicaid insurers
Bernstein expects Democrats to be in a position to take control of the House, while the Senate outcome is too close to call. If some provisions of the healthcare legislation are delayed, pressure on Medicaid enrollment and insurer margins could ease. Hospitals would also benefit, but the firm believes much of the upside is already reflected in valuations.
Bernstein ·
Molina’s rate outlook improves, but membership losses and contract delays weigh on 2027 guidance
Molina’s third-quarter adjusted earnings per share exceeded Bernstein’s expectations but fell by more than half year over year. Preliminary renewal rates for 2027 have improved and could ease pressure from medical costs; membership losses and delays to new contracts, however, weigh on the revenue outlook.
Bernstein ·
Johnson & Johnson bets on a return to faster growth: medical devices bottom out as the new-drug pipeline takes over
Johnson & Johnson management expects operational sales growth to accelerate in 2027 and says the medical devices business had rebounded in October. Longer-term growth depends on new product launches and pipeline progress, particularly expansion into solid tumors.
Goldman Sachs ·
GSK’s two ADCs show encouraging early efficacy, while high-dose safety and competition remain key
Mo-rez achieved a confirmed response rate of 62% in platinum-resistant ovarian cancer, while global data for Ris-rez in small-cell lung cancer were also close to those from a Chinese study. Goldman Sachs sees both assets as competitive, but higher doses were associated with more serious adverse events, and the near-term focus remains oncology drug commercialization.
Goldman Sachs ·
Kangtai Bio’s third-quarter revenue misses Goldman Sachs expectations, while lower impairments lift net profit above forecasts
A declining birth rate and industry competition weighed on revenue. Overseas business grew rapidly but remained a small share of the total. Goldman Sachs cut its revenue forecasts for the next three years, raised its net profit forecasts and maintained a Neutral rating.
Goldman Sachs ·
Lao Bai Xing’s third-quarter profit rose 31% year on year. Why does Goldman Sachs maintain a Neutral rating?
Third-quarter revenue and net profit were broadly in line with Goldman Sachs’ expectations, but the bank believes tight funding conditions and an expansion model reliant on franchising could limit Lao Bai Xing’s ability to gain share during industry consolidation.
Goldman Sachs ·
WuXi AppTec’s new order growth accelerates to 60%; Goldman Sachs raises 2027 earnings forecast
Phase III and commercial small-molecule projects are accelerating orders, while early-stage R&D demand is also recovering. Goldman Sachs sees improved revenue visibility for 2027, but the timing of large-order deliveries, capacity expansion and exchange rates could still cause quarterly fluctuations.
Goldman Sachs ·
Dong-E-E-Jiao’s third-quarter profit falls short of Morgan Stanley’s expectations, putting cash flow and end-market sales in focus
The company’s third-quarter revenue rose 4.1% year on year, while profit was 7% below Morgan Stanley’s forecast. Sales of core ejiao products were weak, while accounts receivable rose and operating cash flow declined. Management expects the latter two metrics to return to normal by year-end.
Morgan Stanley ·